The group's principal activity is to develop, manufacture and commercialize rhigf-1 for the treatment of short stature, diabetes and other endocrine system disorders. The group's product, recombinant human insulin-like growth factor-1 (rhigf-1), is a hormone with a broad range of activity central to growth and metabolism. It commercializes its products in the United States and Europe. The group is in its development stage.
